Navigation Links
Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
Date:4/10/2008

- Laureate To Manufacture Alopexx's Product Candidate -

PRINCETON, N.J., April 10, 2008 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the agreement, Laureate will produce Alopexx's mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and prevention of Staphylococcus aureus infections. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased that Alopexx chose Laureate Pharma as their manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will closely collaborate with the Alopexx team and help them drive their product from development into the clinic."

"Laureate Pharma has a track record of demonstrated expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said Dr. Daniel Vlock, President and CEO of Alopexx. "We look forward to our partnership with Laureate and advancing our antibody therapeutics program into the clinic."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE) (http://www.safeguard.com). For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com .

About Alopexx Pharmaceuticals, LLC

Alopexx Pharmaceuticals was founded to develop a promising new treatment for serious Staphylococcus aureus infections, including those caused by methicillin-resistant strains known as MRSA. In the past decade MRSA has emerged as a major public health problem. Due to the increasing volume of antimicrobial usage around the world, MRSA and many bacteria have become increasingly resistant to most commonly used antibiotics. mAb F598 is a fully human monoclonal antibody that has the potential to serve as an alternative to antibiotics in the fight against MRSA and other S. aureus infections. Unlike antibiotics, monoclonal antibodies will not lead to the development of bacterial resistance. The target of the antibody is a carbohydrate on the bacterial capsule known as PNAG. PNAG has been found to be a critical factor in the virulence and immune response to MRSA as well as non-MRSA staphylococcal infections and is also expressed by other bacterial pathogens. Alopexx Pharmaceuticals, LLC was co-founded by Gerald Pier, PhD and Daniel Vlock, MD. Its aim is to develop and explore the use of novel therapies for the treatment and prevention of MRSA and other serious infections. For more information contact Daniel Vlock, MD at 617-780-1598 or daniel.vlock@alopexx.com or visit http://www.alopexx.com .


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Laureate Pharma Reports Record Growth for 2007
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PUNE, India , December 2, 2016 ... Billion by 2021, growing at a CAGR of 7.3% during the ... segment while hospitals and diagnostic laboratories segment accounted for the largest ... ... Complete report on global immunohistochemistry (IHC) market spread across 225 ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
Breaking Biology Technology:
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):